Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,336 JPY
Change Today -19.00 / -1.40%
Volume 200.2K
As of 2:00 AM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

r-tech ueno ltd (4573) Snapshot

Open
¥1,332
Previous Close
¥1,355
Day High
¥1,354
Day Low
¥1,326
52 Week High
03/9/15 - ¥2,324
52 Week Low
05/28/14 - ¥1,070
Market Cap
25.8B
Average Volume 10 Days
309.2K
EPS TTM
¥71.37
Shares Outstanding
19.3M
EX-Date
03/29/16
P/E TM
18.7x
Dividend
¥35.00
Dividend Yield
2.25%
Current Stock Chart for R-TECH UENO LTD (4573)

Related News

No related news articles were found.

r-tech ueno ltd (4573) Related Businessweek News

No Related Businessweek News Found

r-tech ueno ltd (4573) Details

R-Tech Ueno, Ltd. is engaged in the research, development, manufacture, and sale of pharmaceutical products for the treatment of ophthalmology and dermatology worldwide. The company offers Rescula eye drops to treat glaucoma and ocular hypertension. Its product pipeline comprises Rescula/UF-021, which is in Phase IIb clinical trials to treat retinitis pigmentosa; RU-101 which is in Phase IIa clinical trials for the treatment of dry eye; and RK-023 that is in Phase IIa clinical trials to treat alopecia, as well as in Phase I clinical trials to treat hypotrichosis of the eyelashes. The company is also developing RTU-007 for treating diabetic cataract and retinopathy, and age-related macula degeneration; RTU-1096 for the treatment of atopic dermatitis, contact dermatitis, psoriasis, and diabetic neuropathy. In addition, it offers R and D assistance services, including development of synthetic methods; contract manufacturing of pharmaceuticals; characterization studies; formulation studies; and quality tests and stability tests for drug substances and drug products. Further, the company is engaged in contract manufacturing of injections, eye drops, liquid drugs, liquid-filled hard capsules, solid formulations, and ointments. R-Tech Ueno, Ltd. was founded in 1989 and is headquartered in Tokyo, Japan.

Founded in 1989

r-tech ueno ltd (4573) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

r-tech ueno ltd (4573) Key Developments

R-Tech Ueno, Ltd. to Conduct Collaborative Research with Department of Ophthalmology

R-Tech Ueno, Ltd. has announced plans to conduct collaborative research with a group led by Professor Susumu Ishida and Associate Professor Kousuke Noda of the Department of Ophthalmology. The research is in the application of a new VAP-1 inhibitor (Development Code: RTU-1096), which is under the development for treatment of diabetic retinopathy (DR) and diabetic macular edema. RTU-1096 is a VAP-1 inhibitor, having an anti-inflammatory and immunomodulatory effect that is currently undergoing a Phase I clinical trial in Japan. This collaborative research is to conduct an examination at Hokkaido University to verify the therapeutic effect of RTU-1096 on diabetes ophthalmic complications, such as DR and diabetic macular edema. This examination serves to explore the possibility of the clinical application of the VAP-1 inhibitor for treating DR and diabetic macular edema, in preparation for the POC (Proof of Concept) trials in the future, otherwise known as the Early Phase II clinical trials. Going forward, the company will further accelerate development of the VAP-1 inhibitor as an innovative treatment, setting diabetic complications of DR and diabetic macular edema as the top priority target disease.

R-Tech Ueno, Ltd. Reports Non Consolidated Earnings Results for the Year Ended March 31, 2015; Provides Earnings Outlook for the First Half and Full Year of Fiscal 2016; Announces Year End Dividend, Payable on June 24, 2015; Provides Dividend Outlook for the Fiscal Year Ending March 31, 2016

R-Tech Ueno, Ltd. reported non consolidated earnings results for the year ended March 31, 2015. For the period, the company’s net sales were ¥6,681 million against ¥5,618 million a year ago. Operating income was ¥1,731 million against ¥1,419 million a year ago. Ordinary income was ¥1,884 million against ¥1,477 million a year ago. Net income was ¥1,377 million against ¥1,062 million a year ago. Diluted net income per share was ¥70.87 against ¥54.68 a year ago. Return on equity was 13.0% against 12.3% a year ago. Cash flows from operating activities were ¥1,138 million against ¥1,428 million a year ago. For the fiscal year ended March 31, 2015, the company announced year end dividend of ¥30.00 per share payable on June 24, 2015. For the fiscal year ending March 31, 2016, the company expects year end dividend of ¥35.00 per share. For the first half of fiscal year 2016, the company expects net sales of ¥3,384 million, operating income of ¥594 million, ordinary income of ¥596 million and net income of ¥417 million or ¥21.61 per share. For the fiscal year ending March 31, 2016, the company expects net sales of ¥7,483 million, operating income of ¥2,300 million, ordinary income of ¥2,303 million and net income of ¥1,612 million or ¥83.48 per share.

R-Tech Ueno, Ltd. Signs a Termination Agreement with Sucampo AG

R-Tech Ueno, Ltd. announced it has signed a termination agreement with Sucampo AG (SAG), which terminates, effective May 6, 2015, all license agreements for unoprostone.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4573:JP ¥1,336.00 JPY -19.00

4573 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4573.
View Industry Companies
 

Industry Analysis

4573

Industry Average

Valuation 4573 Industry Range
Price/Earnings 18.9x
Price/Sales 3.9x
Price/Book 2.1x
Price/Cash Flow 18.6x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact R-TECH UENO LTD, please visit www.rtechueno.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.